390 related articles for article (PubMed ID: 28263929)
1. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
2. Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Shibui S
Brain Tumor Pathol; 2013 Oct; 30(4):224-32. PubMed ID: 23494632
[TBL] [Abstract][Full Text] [Related]
3. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
4. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
6. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
Li R; Li H; Yan W; Yang P; Bao Z; Zhang C; Jiang T; You Y
Oncotarget; 2015 Mar; 6(9):7318-24. PubMed ID: 25821160
[TBL] [Abstract][Full Text] [Related]
7. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
9. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
[TBL] [Abstract][Full Text] [Related]
10. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
13. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.
Waqar M; Hanif S; Brodbelt AR; Rathi N; Das K; Zakaria R; Walker C; Jenkinson MD
World Neurosurg; 2015 Jul; 84(1):154-62. PubMed ID: 25779854
[TBL] [Abstract][Full Text] [Related]
15. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
17. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
18. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
[TBL] [Abstract][Full Text] [Related]
19. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
[TBL] [Abstract][Full Text] [Related]
20. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]